X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (4786) 4786
animals (3069) 3069
cell cycle (1943) 1943
apoptosis (1824) 1824
mice (1794) 1794
oncology (1688) 1688
cancer (1612) 1612
cell line, tumor (1605) 1605
phosphorylation (1565) 1565
cell biology (1561) 1561
cyclin-dependent kinases - antagonists & inhibitors (1488) 1488
cyclin-dependent kinases (1472) 1472
female (1348) 1348
biochemistry & molecular biology (1341) 1341
proteins (1316) 1316
kinases (1312) 1312
expression (1234) 1234
male (1040) 1040
apoptosis - drug effects (959) 959
cell proliferation - drug effects (945) 945
signal transduction (938) 938
cell proliferation (886) 886
gene expression (841) 841
research (827) 827
cyclin-dependent kinases - metabolism (814) 814
protein kinase inhibitors - pharmacology (809) 809
activation (800) 800
cyclin-dependent kinase inhibitor p21 - metabolism (798) 798
antineoplastic agents - pharmacology (787) 787
cyclin-dependent kinase inhibitor p21 (710) 710
cells, cultured (697) 697
cell cycle - drug effects (692) 692
enzyme inhibitors - pharmacology (658) 658
tumor suppressor protein p53 - metabolism (628) 628
multidisciplinary sciences (612) 612
proliferation (605) 605
tumors (595) 595
rats (593) 593
research article (586) 586
cyclin-dependent kinase inhibitor p27 (564) 564
growth (557) 557
tumor cells, cultured (556) 556
inhibition (555) 555
signal transduction - drug effects (553) 553
analysis (547) 547
p53 (543) 543
cell line (542) 542
mutation (536) 536
cyclin-dependent kinase inhibitor p21 - genetics (535) 535
cell growth (517) 517
breast cancer (515) 515
biology (513) 513
cell-cycle (505) 505
protein (497) 497
cyclin-dependent kinase 4 - antagonists & inhibitors (490) 490
medicine (486) 486
cyclins - metabolism (475) 475
pharmacology & pharmacy (474) 474
genetic aspects (464) 464
p21 (462) 462
blotting, western (455) 455
cyclin-dependent kinase 2 (451) 451
down-regulation (449) 449
cyclin-dependent kinase (443) 443
in-vitro (439) 439
cyclin-dependent kinase 4 (433) 433
inhibitors (427) 427
health aspects (425) 425
cell cycle proteins - metabolism (423) 423
rna interference (409) 409
science (408) 408
care and treatment (400) 400
dose-response relationship, drug (397) 397
transfection (393) 393
physiological aspects (389) 389
tumor suppressor protein p53 - genetics (388) 388
transcription (387) 387
cyclin-dependent kinase 6 - antagonists & inhibitors (380) 380
protein-serine-threonine kinases - metabolism (380) 380
cyclin-dependent kinase inhibitor p27 - metabolism (377) 377
gene-expression (374) 374
p27 (373) 373
phosphorylation - drug effects (373) 373
protein binding (371) 371
cells (366) 366
cancer therapies (363) 363
gene expression regulation, neoplastic (363) 363
in-vivo (359) 359
cell survival - drug effects (352) 352
retinoblastoma protein - metabolism (352) 352
genes (349) 349
purines - pharmacology (343) 343
flow cytometry (339) 339
cell cycle proteins (337) 337
differentiation (337) 337
chemotherapy (331) 331
middle aged (331) 331
cell division (328) 328
gene (326) 326
metastasis (322) 322
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6835) 6835
Japanese (26) 26
Chinese (12) 12
German (10) 10
French (4) 4
Portuguese (3) 3
Czech (1) 1
Russian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Nature reviews. Cancer, ISSN 1474-1768, 2017, Volume 17, Issue 2, pp. 93 - 115
.... Proliferation depends on progression through four distinct phases of the cell cycle G0/G1, S, G2 and M which is regulated by several cyclin-dependent kinases (CDKs... 
INVESTIGATIONAL AURORA KINASE | PHASE-II TRIAL | POLO-LIKE-KINASE | EARLY EMBRYONIC-DEVELOPMENT | DINACICLIB SCH 727965 | ADVANCED SOLID TUMORS | ONCOLOGY | PREVENTS TUMOR-GROWTH | VOLASERTIB BI 6727 | DEPENDENT KINASE INHIBITOR | SMALL-MOLECULE INHIBITOR | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Humans | Checkpoint Kinase 1 - physiology | Aurora Kinase A - antagonists & inhibitors | Cyclin-Dependent Kinase 2 - physiology | Cell Cycle Proteins - antagonists & inhibitors | Protein-Tyrosine Kinases - physiology | Aurora Kinase A - physiology | Protein-Serine-Threonine Kinases - antagonists & inhibitors | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Proto-Oncogene Proteins - antagonists & inhibitors | Signal Transduction | Protein-Serine-Threonine Kinases - physiology | Checkpoint Kinase 1 - antagonists & inhibitors | Clinical Trials as Topic | Neoplasms - drug therapy | Animals | Cyclin-Dependent Kinase 4 - physiology | Nuclear Proteins - antagonists & inhibitors | Proto-Oncogene Proteins - physiology | Cyclin-Dependent Kinase 2 - antagonists & inhibitors | Cyclin-Dependent Kinase 6 - physiology | Nuclear Proteins - physiology | Cell Cycle Proteins - physiology | Protein-Tyrosine Kinases - antagonists & inhibitors | Proteins | Care and treatment | Usage | MicroRNA | Cell cycle | Research | Cancer
Journal Article
JNCI : Journal of the National Cancer Institute, ISSN 1460-2105, 2017, Volume 109, Issue 5
Journal Article
Cancer discovery, ISSN 2159-8274, 04/2016, Volume 6, Issue 4, pp. 353 - 367
Journal Article
The lancet oncology, ISSN 1470-2045, 2015, Volume 16, Issue 1, pp. 25 - 35
Summary Background Palbociclib (PD-0332991) is an oral, small-molecule inhibitor of cyclin-dependent kinases (CDKs... 
Hematology, Oncology and Palliative Medicine | SURVIVAL | EXEMESTANE | ONCOLOGY | CELL-CYCLE | POSTMENOPAUSAL WOMEN | HER2 | PLUS | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Piperazines - administration & dosage | Triazoles - administration & dosage | Receptor, ErbB-2 - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Receptors, Estrogen - analysis | Molecular Targeted Therapy | North America | Nitriles - administration & dosage | Breast Neoplasms - enzymology | Time Factors | Postmenopause | Female | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Republic of Korea | Aromatase Inhibitors - administration & dosage | Pyridines - administration & dosage | Drug Administration Schedule | Administration, Oral | Biomarkers, Tumor - analysis | Europe | Proportional Hazards Models | Cyclin-Dependent Kinase Inhibitor p16 - genetics | Treatment Outcome | Cyclin-Dependent Kinase 6 - metabolism | Cyclin-Dependent Kinase 4 - metabolism | Breast Neoplasms - drug therapy | Disease-Free Survival | Protein Kinase Inhibitors - administration & dosage | Breast Neoplasms - genetics | Cyclin D1 - genetics | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | South Africa | Aged | Biomarkers, Tumor - genetics | Receptor, ErbB-2 - analysis | Antimitotic agents | Care and treatment | Oncology, Experimental | Estrogen | Breast cancer | Research | Antineoplastic agents | Phosphotransferases | Cancer
Journal Article
Proceedings of the National Academy of Sciences - PNAS, ISSN 1091-6490, 2019, Volume 116, Issue 36, pp. 17990 - 18000
Cyclin-dependent kinase 4/6 (CDK4/6) inhibitors are an established treatment in estrogen receptor-positive breast cancer and are currently in clinical development in melanoma, a tumor that exhibits high rates of CDK4 activation... 
PRMT5 | METHYLATION | MULTIDISCIPLINARY SCIENCES | VULNERABILITY | COMBINATION | acquired resistance | p53 | BREAST-CANCER | PALBOCICLIB | CDK4 | THERAPEUTIC TARGET | ARGININE METHYLTRANSFERASE | GROWTH | RESISTANCE | MDM4 | METHYLOSOME | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Cyclin-Dependent Kinase 4 - genetics | Humans | Protein-Arginine N-Methyltransferases - antagonists & inhibitors | Drug Resistance, Neoplasm | Tumor Suppressor Protein p53 - genetics | MCF-7 Cells | Melanoma - genetics | HEK293 Cells | Cell Cycle Proteins - genetics | Protein-Arginine N-Methyltransferases - genetics | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Melanoma - metabolism | Proto-Oncogene Proteins - metabolism | Cyclin-Dependent Kinase 2 - metabolism | Cell Cycle Proteins - metabolism | Cyclin-Dependent Kinase 6 - genetics | Tumor Suppressor Protein p53 - metabolism | Cyclin-Dependent Kinase 2 - genetics | Proto-Oncogene Proteins - genetics | Cyclin-Dependent Kinase 6 - metabolism | Melanoma - pathology | Cyclin-Dependent Kinase 4 - metabolism | Piperazines - pharmacology | Protein-Arginine N-Methyltransferases - metabolism | Melanoma - drug therapy | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | RNA | Tumor proteins | Analysis | Melanoma | GTP-binding protein | p53 Protein | Estrogens | Menopause | mRNA | Kinases | Cyclin-dependent kinase 4 | Proteins | Cell activation | Pancreatic carcinoma | Arginine | Inhibition | Pancreas | Esophageal carcinoma | Splicing | Cyclin-dependent kinases | Protein arginine methyltransferase | Breast cancer | Esophagus | Cyclin-dependent kinase 2 | Sensitivity | Inhibitors | Tumor suppressor genes | Tumors | Biological Sciences | PNAS Plus
Journal Article
Nature (London), ISSN 1476-4687, 2017, Volume 548, Issue 7668, pp. 471 - 475
Cyclin-dependent kinases 4 and 6 (CDK4/6) are fundamental drivers of the cell cycle and are required for the initiation and progression of various malignancies(1,2... 
BREAST-CANCER | CELLS | METHYLATION | MULTIDISCIPLINARY SCIENCES | SENESCENCE | EXPRESSION | REQUIREMENT | Cyclin-Dependent Kinase 6 - antagonists & inhibitors | Viruses - genetics | Breast Neoplasms - immunology | Humans | Transcriptome | T-Lymphocytes, Regulatory - immunology | T-Lymphocytes, Regulatory - cytology | Female | Biological Mimicry - drug effects | Phosphorylation - drug effects | Cyclin-Dependent Kinase 4 - antagonists & inhibitors | Disease Models, Animal | Viruses - drug effects | Viruses - immunology | Antigen Presentation - immunology | Breast Neoplasms - drug therapy | T-Lymphocytes, Regulatory - drug effects | Animals | Breast Neoplasms - genetics | Repressor Proteins - biosynthesis | Signal Transduction - drug effects | Breast Neoplasms - pathology | Cell Cycle Checkpoints - drug effects | Protein Kinase Inhibitors - therapeutic use | RNA, Double-Stranded - genetics | Cell Line, Tumor | Interferons - metabolism | Antigen Presentation - drug effects | Cell Proliferation - drug effects | Mice | Protein Kinase Inhibitors - pharmacology | Oncology, Experimental | Cancer cells | Physiological aspects | Research | Protein kinases | Immunity | Cyclins | Cancer | Cell proliferation | Flow cytometry | Animal models | Phosphorylation | Senescence | Peptides | Genomics | Immune clearance | Cytotoxicity | Lymphocytes T | Genomes | Kinases | Cancer therapies | Cyclin-dependent kinase 4 | E2F protein | Breast carcinoma | Cell growth | Lymphocytes | New combinations | Cell cycle | Inhibition | Deoxyribonucleic acid--DNA | Immune system | Antigen presentation | Medical research | Immune response | Immunoregulation | Intracellular levels | Double-stranded RNA | Breast cancer | Pharmacology | Gene expression | Ribonucleic acid--RNA | Inhibitors | Immune checkpoint | Immunogenicity | DNA methyltransferase | Interferon | Retinoblastoma | Tumors | Apoptosis
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2015, Volume 373, Issue 3, pp. 209 - 219
Journal Article